Atlas Trials

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Clinical trial NCT01066390 · COMPLETED

Trial details

NCT number
NCT01066390
Sponsor
Bart Neyns
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Melanoma
Start date
2009-12-01
Primary completion
2013-11-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.